The DOI matches its Crossref record.
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Recently developed PI3K α inhibitors such as STX478 may be useful for overcoming resistance to KRAS inhibitors [120, 121].”
Metadata
- Authors
- Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., Soyano, A., De Miguel, M., Doger de Spéville, B., Daniele, G., O'Shaughnessy, J., Hernandez Guerrero, T. C., Wesolowski, R., Saura Manich, C., Chao, M., & Juric, D.
- Affiliations
- University Hospitals of Cleveland (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Mary Crowley Cancer Research Center (US)
- Institut Bergonié (FR)
- University of Colorado Anschutz (US)
- Moffitt Cancer Center (US)
- Agostino Gemelli University Polyclinic (IT)
- The Ohio State University Wexner Medical Center (US)
- Scorpion Therapeutics (United States) (US)
- Harvard University (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 35
- Pages
- S1220
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4402565463
- Cited by
- 9
- References
- 0
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 1
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Spectrum Pharmaceuticals
- Alnylam Pharmaceuticals
- Les Laboratories Pierre Fabre
- Incyte
- Carrick Therapeutics
- MacroGenics
- G1 Therapeutics
- Seagen
- Eisai
- European Society for Medical Oncology
- PharmaMar
- Ipsen
- Symphogen
- Aptitude Health
- Genentech
- Samsung
- Chugai Pharmaceutical
- Loxo Oncology
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- PI3Kα inhibitor, advanced solid tumors, oral anticancer drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
